South Denver Cardiology
Back to Trials

VICTORIA

Short Description

Trial of MK-1242 (vericiguat) in subjects with heart failure with reduced EF

VICTORIA: A randomized, placebo-controlled, parallel-group, multi-centered, double-blind, event driven trial of MK-1242 (vericiguat) in subjects with heart failure with reduced ejection fraction (HFrEF).  The safety and efficacy of MK-1242 (vericiguat) compared to placebo, on a background of standard of care will be evaluated.  Vericiguat is a novel oral soluble guanylate cyclase stimulator in development for chronic HF.

 

Questions: Call Mary Soltau 303-703-2191 or Rebecca Wimmer 303-715-2275

South Denver Cardiology
Latest posts by South Denver Cardiology (see all)

Recommend

  • This field is for validation purposes and should be left unchanged.
  • MM slash DD slash YYYY
  • What questions do you have regarding your bill?